(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...
Organon to buy Roivant's dermatology unit for up to $1.2 billion 2:06 PM UTC Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching ...
To support pediatric eczema patients, Dermavant created the My Skin, My Story digital storytelling platform to address not just the clinical treatment of chronic skin conditions, but also the mental ...